Cargando…

Results of the European EDITH nephrologist survey on factors influencing treatment modality choice for end-stage kidney disease

BACKGROUND: Access to forms of dialysis, kidney transplantation (Tx) and comprehensive conservative management (CCM) for patients with end-stage kidney disease (ESKD) varies across European countries. Attitudes of nephrologists, information provision and decision-making may influence this access and...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jong, Rianne W, Jager, Kitty J, Vanholder, Raymond C, Couchoud, Cécile, Murphy, Mark, Rahmel, Axel, Massy, Ziad A, Stel, Vianda S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719583/
https://www.ncbi.nlm.nih.gov/pubmed/33486525
http://dx.doi.org/10.1093/ndt/gfaa342
_version_ 1784624965808553984
author de Jong, Rianne W
Jager, Kitty J
Vanholder, Raymond C
Couchoud, Cécile
Murphy, Mark
Rahmel, Axel
Massy, Ziad A
Stel, Vianda S
author_facet de Jong, Rianne W
Jager, Kitty J
Vanholder, Raymond C
Couchoud, Cécile
Murphy, Mark
Rahmel, Axel
Massy, Ziad A
Stel, Vianda S
author_sort de Jong, Rianne W
collection PubMed
description BACKGROUND: Access to forms of dialysis, kidney transplantation (Tx) and comprehensive conservative management (CCM) for patients with end-stage kidney disease (ESKD) varies across European countries. Attitudes of nephrologists, information provision and decision-making may influence this access and nephrologists may experience several barriers when providing treatments for ESKD. METHODS: We surveyed European nephrologists and kidney transplant surgeons treating adults with ESKD about factors influencing modality choice. Descriptive statistics were used to compare the opinions of professionals from European countries with low–, middle– and high–gross domestic product purchasing power parity (GDP PPP). RESULTS: In total, 681 professionals from 33 European countries participated. Respondents from all GDP categories indicated that ∼10% of patients received no information before the start of renal replacement therapy (RRT) (P = 0.106). Early information provision and more involvement of patients in decision-making were more frequently reported in middle- and high-GDP countries (P < 0.05). Professionals’ attitudes towards several treatments became more positive with increasing GDP (P < 0.05). Uptake of in-centre haemodialysis was sufficient to 73% of respondents, but many wanted increased uptake of home dialysis, Tx and CCM. Respondents experienced different barriers according to availability of specific treatments in their centre. The occurrence of barriers (financial, staff shortage, lack of space/supplies and patient related) decreased with increasing GDP (P < 0.05). CONCLUSIONS: Differences in factors influencing modality choice when providing RRT or CCM to adults with ESKD were found among low-, middle- and high-GDP countries in Europe. Therefore a unique pan-European policy to improve access to treatments may be inefficient. Different policies for clusters of countries could be more useful.
format Online
Article
Text
id pubmed-8719583
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-87195832022-01-05 Results of the European EDITH nephrologist survey on factors influencing treatment modality choice for end-stage kidney disease de Jong, Rianne W Jager, Kitty J Vanholder, Raymond C Couchoud, Cécile Murphy, Mark Rahmel, Axel Massy, Ziad A Stel, Vianda S Nephrol Dial Transplant Original Article BACKGROUND: Access to forms of dialysis, kidney transplantation (Tx) and comprehensive conservative management (CCM) for patients with end-stage kidney disease (ESKD) varies across European countries. Attitudes of nephrologists, information provision and decision-making may influence this access and nephrologists may experience several barriers when providing treatments for ESKD. METHODS: We surveyed European nephrologists and kidney transplant surgeons treating adults with ESKD about factors influencing modality choice. Descriptive statistics were used to compare the opinions of professionals from European countries with low–, middle– and high–gross domestic product purchasing power parity (GDP PPP). RESULTS: In total, 681 professionals from 33 European countries participated. Respondents from all GDP categories indicated that ∼10% of patients received no information before the start of renal replacement therapy (RRT) (P = 0.106). Early information provision and more involvement of patients in decision-making were more frequently reported in middle- and high-GDP countries (P < 0.05). Professionals’ attitudes towards several treatments became more positive with increasing GDP (P < 0.05). Uptake of in-centre haemodialysis was sufficient to 73% of respondents, but many wanted increased uptake of home dialysis, Tx and CCM. Respondents experienced different barriers according to availability of specific treatments in their centre. The occurrence of barriers (financial, staff shortage, lack of space/supplies and patient related) decreased with increasing GDP (P < 0.05). CONCLUSIONS: Differences in factors influencing modality choice when providing RRT or CCM to adults with ESKD were found among low-, middle- and high-GDP countries in Europe. Therefore a unique pan-European policy to improve access to treatments may be inefficient. Different policies for clusters of countries could be more useful. Oxford University Press 2021-01-22 /pmc/articles/PMC8719583/ /pubmed/33486525 http://dx.doi.org/10.1093/ndt/gfaa342 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
de Jong, Rianne W
Jager, Kitty J
Vanholder, Raymond C
Couchoud, Cécile
Murphy, Mark
Rahmel, Axel
Massy, Ziad A
Stel, Vianda S
Results of the European EDITH nephrologist survey on factors influencing treatment modality choice for end-stage kidney disease
title Results of the European EDITH nephrologist survey on factors influencing treatment modality choice for end-stage kidney disease
title_full Results of the European EDITH nephrologist survey on factors influencing treatment modality choice for end-stage kidney disease
title_fullStr Results of the European EDITH nephrologist survey on factors influencing treatment modality choice for end-stage kidney disease
title_full_unstemmed Results of the European EDITH nephrologist survey on factors influencing treatment modality choice for end-stage kidney disease
title_short Results of the European EDITH nephrologist survey on factors influencing treatment modality choice for end-stage kidney disease
title_sort results of the european edith nephrologist survey on factors influencing treatment modality choice for end-stage kidney disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719583/
https://www.ncbi.nlm.nih.gov/pubmed/33486525
http://dx.doi.org/10.1093/ndt/gfaa342
work_keys_str_mv AT dejongriannew resultsoftheeuropeanedithnephrologistsurveyonfactorsinfluencingtreatmentmodalitychoiceforendstagekidneydisease
AT jagerkittyj resultsoftheeuropeanedithnephrologistsurveyonfactorsinfluencingtreatmentmodalitychoiceforendstagekidneydisease
AT vanholderraymondc resultsoftheeuropeanedithnephrologistsurveyonfactorsinfluencingtreatmentmodalitychoiceforendstagekidneydisease
AT couchoudcecile resultsoftheeuropeanedithnephrologistsurveyonfactorsinfluencingtreatmentmodalitychoiceforendstagekidneydisease
AT murphymark resultsoftheeuropeanedithnephrologistsurveyonfactorsinfluencingtreatmentmodalitychoiceforendstagekidneydisease
AT rahmelaxel resultsoftheeuropeanedithnephrologistsurveyonfactorsinfluencingtreatmentmodalitychoiceforendstagekidneydisease
AT massyziada resultsoftheeuropeanedithnephrologistsurveyonfactorsinfluencingtreatmentmodalitychoiceforendstagekidneydisease
AT stelviandas resultsoftheeuropeanedithnephrologistsurveyonfactorsinfluencingtreatmentmodalitychoiceforendstagekidneydisease